Login
$AXGN
$55.38 -$0.55 (0.98%) Live

$AXGN 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Regulation FD Disclosure

Prostate Nerve Reconstruction Investor Event November 9, 2026

28 Oct 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ALACHUA and TAMPA, FL – October 28, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and busi...

01 Oct 2026 8-K: Regulation FD Disclosure

Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

10 Sep 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more

Axogen, Inc., a Minnesota corporation (the “Company”) confirms its agreement with BofA Securities, Inc. (“BofA Securities”), Jefferies LLC (“Jefferies”), Wells Fargo Securities, LLC (“Wells Fargo”) and each of the other Underwriters name...

29 Jul 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ALACHUA and TAMPA, FL – July 29, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and busines...

23 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 23, 2026, Axogen, Inc. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”), at which a total of 45,364,808 shares of common stock of the Company, out of a total 53,177,824 shares of common stock ou...

28 Apr 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ALACHUA and TAMPA, FL – April 28, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and busine...

24 Feb 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ALACHUA and TAMPA, FL – February 24, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and bus...

23 Jan 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Axogen, Inc., a Minnesota corporation (the “Company”) confirms its agreement with Wells Fargo Securities, LLC (“Wells Fargo”) and Mizuho Securities USA LLC (“Mizuho”) and each of the other Underwriters named in Schedule A hereto (collect...

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

1 Making Nerve Repair an Expected Standard of Care A commitment to restoring health, improving quality of life, and advancing peripheral nerve care for every patient. Michael Dale, President & CEO January 2026

05 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

This Amended and Restated Confidentiality, Intellectual Property, Non-Competition and Non-Solicitation Agreement (this “Amended Amended IP and NCNS Agreement”) is effective as of December 5, 2025 (the “Effective Date”) by and between Axo...

04 Dec 2025 8-K: Regulation FD Disclosure; Other Events

ALACHUA, FL and TAMPA, FL – December 3, 2025 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function, today announced that the U.S. Food...

29 Oct 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ALACHUA and TAMPA, FL – October 29, 2025 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and busi...

25 Aug 2025 8-K: Regulation FD Disclosure

ALACHUA, FL and TAMPA, FL – August 25, 2025 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that the U.S. Food and...

05 Aug 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ALACHUA and TAMPA, FL – August 5, 2025 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and busine...

20 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 18, 2025, Axogen, Inc. (the “Company”) held its 2025 annual meeting of shareholders (the “Annual Meeting”), at which a total of 37,190,480 shares of common stock of the Company, out of a total 45,534,866 shares of common stock ou...

08 May 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), effective as of May 12, 2025 (the “Effective Date”), is made by and between AXOGEN CORPORATION, a Delaware corporation (“AXOGEN”), and Lindsey Hartley (“Employee”) (collectively, the...

07 Apr 2025 8-K: Regulation FD Disclosure

On April 2, 2025, President Donald J. Trump announced a plan that would implement a broad range of tariffs on goods imported into the United States. Axogen, Inc. (the "Company") anticipates minimal impact from these tariffs, as well as f...

04 Mar 2025 8-K: Regulation FD Disclosure

The Standard of Nerve Care Investor Presentation March 4th, 2025 1

25 Feb 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ALACHUA and TAMPA, FL – February 25, 2025 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights fo...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support